# Moderna, Inc.: overview

MRNA · Nasdaq · CIK 1682852 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mrna.md) · [Financials](/companies/mrna/financials.md) · [Filings](/companies/mrna/filings.md) · [Insiders](/companies/mrna/insiders.md)

Latest reported revenue: [$145.0m](/filings/0001682852-26-000150.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Jul 31, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001682852-26-000150).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,862](/filings/0001682852-25-000075.md) | [966 d](/filings/0001682852-26-000033.md) | [108](/filings/0001682852-26-000060.md) | [142](/filings/0001682852-26-000150.md) | [1,016](/filings/0001682852-25-000075.md) | [678 d](/filings/0001682852-26-000033.md) | [389](/filings/0001682852-26-000060.md) | [145](/filings/0001682852-26-000150.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(3.8%)](/filings/0001682852-25-000075.md) | [(129.0%) d](/filings/0001682852-26-000033.md) | [(972.2%)](/filings/0001682852-26-000060.md) | [(638.7%)](/filings/0001682852-26-000150.md) | [(25.6%)](/filings/0001682852-25-000075.md) | [(126.4%) d](/filings/0001682852-26-000033.md) | [(356.8%)](/filings/0001682852-26-000060.md) | [(562.1%)](/filings/0001682852-26-000150.md) |
| Net margin | % | [0.7%](/filings/0001682852-25-000075.md) | [(115.9%) d](/filings/0001682852-26-000033.md) | [(899.1%)](/filings/0001682852-26-000060.md) | [(581.0%)](/filings/0001682852-26-000150.md) | [(19.7%)](/filings/0001682852-25-000075.md) | [(121.8%) d](/filings/0001682852-26-000033.md) | [(345.2%)](/filings/0001682852-26-000060.md) | [(539.3%)](/filings/0001682852-26-000150.md) |
| Diluted EPS | $ per share | [0.03](/filings/0001682852-25-000075.md) | not reported | [(2.52)](/filings/0001682852-26-000060.md) | [(2.13)](/filings/0001682852-26-000150.md) | [(0.51)](/filings/0001682852-25-000075.md) | not reported | [(3.40)](/filings/0001682852-26-000060.md) | [(1.97)](/filings/0001682852-26-000150.md) |
| Free cash flow | $m | [(1,717) d](/filings/0001682852-25-000075.md) | [303 d](/filings/0001682852-26-000033.md) | [(1,154)](/filings/0001682852-26-000060.md) | [(922) d](/filings/0001682852-26-000150.md) | [(880) d](/filings/0001682852-25-000075.md) | [891 d](/filings/0001682852-26-000033.md) | [(692)](/filings/0001682852-26-000060.md) | [(563) d](/filings/0001682852-26-000150.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [18.5](/filings/0001682852-24-000015.md) | [19.3](/filings/0001682852-25-000022.md) | [6.8](/filings/0001682852-26-000033.md) | [3.2](/filings/0001682852-26-000033.md) | [1.9](/filings/0001682852-26-000033.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [72.0%](/filings/0001682852-24-000015.md) | [48.9%](/filings/0001682852-25-000022.md) | [(61.9%)](/filings/0001682852-26-000033.md) | [(121.9%)](/filings/0001682852-26-000033.md) | [(158.1%)](/filings/0001682852-26-000033.md) |
| Net margin | % | [66.1%](/filings/0001682852-24-000015.md) | [43.4%](/filings/0001682852-25-000022.md) | [(68.8%)](/filings/0001682852-26-000033.md) | [(110.0%)](/filings/0001682852-26-000033.md) | [(145.2%)](/filings/0001682852-26-000033.md) |
| Diluted EPS | $ per share | [28.29](/filings/0001682852-24-000015.md) | [20.12](/filings/0001682852-25-000022.md) | [(12.33)](/filings/0001682852-26-000033.md) | [(9.28)](/filings/0001682852-26-000033.md) | [(7.26)](/filings/0001682852-26-000033.md) |
| Free cash flow | $bn | [13.3](/filings/0001682852-24-000015.md) | [4.6](/filings/0001682852-25-000022.md) | [(3.8)](/filings/0001682852-26-000033.md) | [(4.1)](/filings/0001682852-26-000033.md) | [(2.1)](/filings/0001682852-26-000033.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/mrna/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $3.63bn | 51,859,891 |  | Added +6,187,867 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $2.14bn | 30,599,409 |  | Added +963,533 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.63bn | 23,208,792 |  | Added +336,334 |
| [Capital World Investors](/funds/1422849.md) | 2026-06-30 | $1.56bn | 22,276,996 |  | Added +3,579,302 |
| [BAILLIE GIFFORD & CO](/funds/1088875.md) | 2026-06-30 | $1.28bn | 18,206,778 |  | Reduced −1,779,098 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $1.10bn | 15,726,193 |  | Added +864,784 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $1.09bn | 15,581,313 |  | Reduced −35,054 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $678.8m | 9,710,335 |  | Added +275,203 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $668.0m | 9,538,094 |  | Added +1,066,831 |
| [Theleme Partners LLP](/funds/1511881.md) | 2026-06-30 | $564.3m | 8,057,571 |  | Added +9,326 |

## Recent filings

[All 1,496 filings](/companies/mrna/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-30 | 11:15 ET | [8-K](/filings/0001193125-26-408289.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-408289 |
| 2026-09-01 | 20:37 ET | [8-K](/filings/0001193125-26-378505.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-378505 |
| 2026-07-31 | 20:17 ET | [10-Q](/filings/0001682852-26-000150.md) | Quarterly report, period 2026-06-30 | 0001682852-26-000150 |
| 2026-07-31 | 11:03 ET | [8-K](/filings/0001682852-26-000147.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001682852-26-000147 |
| 2026-07-08 | 11:08 ET | [8-K](/filings/0001682852-26-000134.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001682852-26-000134 |
| 2026-05-11 | 10:06 ET | [8-K](/filings/0001682852-26-000101.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001682852-26-000101 |
| 2026-05-01 | 20:10 ET | [10-Q](/filings/0001682852-26-000060.md) | Quarterly report, period 2026-03-31 | 0001682852-26-000060 |
| 2026-05-01 | 10:32 ET | [8-K](/filings/0001682852-26-000057.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001682852-26-000057 |
| 2026-03-16 | 20:31 ET | [DEF 14A](/filings/0001308179-26-000081.md) | Proxy statement, period 2026-05-06 | 0001308179-26-000081 |
| 2026-03-05 | 01:20 ET | [8-K](/filings/0001682852-26-000047.md) | 1.01 Entry into a material agreement | 0001682852-26-000047 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001682852-26-000033.md), filed Feb 20, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/e3dd18d5-1304-4087-82bb-8f5cd7fb3434)

## About the filer

- CIK: 1682852
- Tickers: MRNA
- Exchange: Nasdaq
- SIC code: 2836 Biological Products, (No Diagnostic Substances)
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.